An enantiomer-selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine, and liver microsomes

Journal of Analytical Toxicology

Volumn 32, Issue 3, 2008, Pages 208-219

  Moody, David E ^a   Lin, Shen Nan ^a   Chang, Yan ^a   Lamm, Lolita ^a   Greenwald, Mark K ^b   Ahmed, Mahmoud S ^c  

^a UNIVERSITY OF UTAH   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; METHADONE;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STABILITY; DRUG URINE LEVEL; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; LIVER MICROSOME; NORMAL HUMAN; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 41649103033     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/32.3.208     Document Type: Article

References (57)

1. M.J. Garrido and I.F. Troconiz. Methadone: a review of its pharmacokinetic/pharmacodynamic properties. J. Pharmacol. Toxicol. 42: 61-66 (1999).
2. C.B. Eap, T. Buclin, and P. Baumann. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41: 1153-1193 (2002).
3. Substance Abuse and Mental Health Services Administration. Methadone-associated mortality: background briefing report. http://www.dpt. samhsa.gov/medications/methadonemortality2003/methadone_mortality_briefing.pdf, April 2007.
4. E.M. Caravati, T. Grey, B. Nangle, R.T. Rolfs, and C.A. Peterson-Poruceznik. Increase in poisoning deaths caused by non-illicit drugs-Utah, 1991-2003. MMWR Morb. Mortal Wkly. Rep. 54: 33-36 (2005).
5. L.J. Paulozzi. Opioid analgesis involvement in drug abuse deaths in American metropolitan areas. Am. J. Public Health 96: 1755-1757 (2006).
6. L.J. Paulozzi and G.W. Ryan. Opioid analgesics and rates of fatal drug poisoning in the United States. Am. J. Prev. Med. 31: 506-511 (2006).
7. T. Hampton. Methadone alert. J. Am. Med. Assoc. 297: 354 (2007).
8. R.C. Dart, G.E.Woody, and H.D. Kleber. Prescribing methadone as an analgesic. Ann. Int. Med. 143: 620 (2005).
9. N. Dasgupta, E.D. Kramer, M.A. Zalman, S. Carino, M.Y. Smith, J.D. Haddox, and C. Wright. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend. 82: 135-142 (2006).
10. J.T. Zerzan, N.E. Morden, S. Soumerai, D. Ross-Degman, E. Roughhead, F. Zhang, L. Simoni-Wastila, and S.D. Sullivan. Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med. Care 44: 1005-1010 (2006).
11. M.J. Kreek. Drug interactions in humans related to drug abuse and its treatment. Mod. Meth. Pharmacol. 6: 265-282 (1990).
12. A. Ferrari, C.P.R. Coccia, A. Bertolini, and E. Sternieri.Methadone - metabolism, pharmacokinetics and interactions. Pharmacol. Res. 50: 551-559 (2004).
13. E.F. McCance-Katz. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: The importance of drug interactions between opioids and antiretroviral agents. Clin. Infect. Dis. 41(Suppl 1): S89-S95 (2005).
14. C.B. Pert and S.H. Snyder. Opiate receptor: demonstration in nervous tissue. Science 179: 1011-1014 (1973).
15. K. Kristensen, C.B. Christensen, and L.L. Christrup. The mu1, mu2, delta, kappa opioid receptor binding properties of methadone stereoisomers and morphine. Life Sci. 56: 45-50 (1995).
16. V.P. Dole and M.E. Nyswander. Rehabilitation of heroin addicts after blockade with methadone. N. Y. State Med. J. 66: 2011-2017 (1966).
17. C.C. Scott, E.B. Robbins, and K.K. Chen. Pharmacological comparison of the optical isomers of methadone. J. Pharmacol. Exp. Ther. 92: 282-286 (1948).
18. G.D. Olsen, H.A.Wendel, J.D. Livermore, R.M. Leger, R.K. Lynn, and N. Gerber. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin. Pharmacol. Ther. 21: 147-157 (1977).
19. M.J. Kreek, D.L. Hachey, and P.D. Klein. Stereoselective disposition of methadone in man. Life Sci. 24: 925-932 (1979).
20. K. Kristensen, T. Blemmer, H.R. Angelo, L.L. Christrup, N.E. Drenck, S.N. Rasmussen, and P. Sjorgren. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther. Drug Monit. 18: 221-227 (1996).
21. D.J.R. Foster, A.A. Somogyi, K.R. Dyer, J.M.White, and F. Bocher. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br. J. Clin. Pharmacol. 50: 427-440 (2000).
22. D.W. Boulton, P. Arnaud, and C.L. DeVane. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin. Pharmacol. Ther. 70: 48-57 (2001).
23. J. Hanna, D.J.R. Foster, A. Salter, A.A. Somogyi, J.M. White, and F. Bochner.Within- and between-subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. Br. J. Clin. Pharmacol. 60: 404-413 (2005).
24. K. Auret, C.R. Goucke, K.F. Ilett, M. Page-Sharp, F. Boyd, and T.E. Oh. Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. Ther. Drug Monit. 28: 359-366 (2006).
25. M.E. Rodriguez-Rosas, J.G. Medrano, D.H. Epstein, E.T. Moolchan, K.L. Preston, and I.W. Wainer. Determination of total and free concentrations of the enantiomers of methadone and its metabolite (2-ethylidene-1,5-dimethyl-3,3- diphenyl-pyrrolidine) in human plasma by enantioselective liquid chromatography with mass spectrometric detection. J. Chromatogr. A 1073: 237-248 (2005).
26. C. Iribarne, F. Berthou, S. Baird, Y. Dreano, D. Picart, J.P. Bail, P. Beaune, and J.F. Menez. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9: 365-373 (1996).
27. D.E. Moody, M.E. Alburges, R.J. Parker, J.M. Collins, and J.M. Strong. The involvement of cytochrome P450 3A in the N-demethylation of l-α-acetylmethadol (LAAM), norLAAM and methadone. Drug Metab. Dispos. 25: 1347-1353 (1997).
28. D.J.R. Foster, A.A. Somogyi, and F. Bochner. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br. J. Clin. Pharmacol. 47: 403-412 (1999).
29. J.S. Wang and C.L. DeVane. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab. Dispos. 31: 742-747 (2003).
30. F. Prost and W. Thormann. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes™): application to the chiral metabolism of mephenytoin and methadone. Electrophoresis 24: 2577-2587 (2003).
31. J.G. Gerber, R.J. Rhodes, and J. Gal. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16: 36-44 (2004).
32. E.D. Kharasch, C. Hoffer, D. Whittington, and P. Sheffels. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin. Pharmacol. Ther. 76: 250-269 (2004).
33. R.A. Totah, K.E. Allen, P. Sheffels, D. Whittington, and E.D. Kharasch. Enantiomeric interactions and stereoselective human methadone metabolism. J. Pharmacol. Exp. Ther. 321: 389-399 (2007).
34. S. Crettol, J.J. Deglon, J. Besson, M. Croquette-Krokkar, I. Gothuey, R. Hammig, M. Monnat, H. Huttemann, P. Baumann, and C.B. Eap. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78: 593-604 (2005).
35. S. Crettol, J.J. Deglon, J. Besson, M. Croquette-Krokar, R. Hammig, I. Gothuey, M. Monnat, and C.B. Eap. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 80: 668-681 (2006).
36. T.N. Nanovskaya, S.V. Deshmukh, I.A. Nekhayeva, O.L. Zharikova, G.D.V. Hankins, and M.S. Ahmed. Methadone metabolism by human placenta. Biochem. Pharmacol. 68: 583-591 (2004).
37. D.Whittington, P. Sheffels, and E.D. Kharasch. Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry. J. Chromatogr. B 809: 313-321 (2004).
38. R. Dams, C.M. Murphy, R.E. Choo, W.E. Lambert, A.P. De Leenheer, and M.A. Huestis. LC-atmospheric pressure chemical ionization-MS/MS analysis of multiple illicit drugs, methadone, and their metabolites in oral fluid following protein precipitation. Anal. Chem. 75: 798-804 (2003).
39. T. Kelly, P. Doble, and M. Dawson. Chiral analysis of methadone and its major metabolites (EDDP and EMDP) by liquid chromatography-mass spectrometry. J. Chromatogr. B 814: 315-323 (2005).
40. R.E. Choo, C.M. Murphy, H.E. Jones, and M.A. Huestis. Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. J. Chromatogr. B 814: 369-373 (2005).
41. M.L. Etter, S. George, K. Graybiel, J. Eichhorst, and D.C. Lehotay. Determination of free and protein-bound methadone and its major metabolite EDDP: enantiomeric separation and quantitation by LC/MS/MS. Clin. Biochem. 38: 1095-1102 (2005).
42. O. Quintela, P. Lopez, A.M. Bermejo, and M. Lopez-Rivadulla. Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine and alprazolam in human plasma by liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B 834: 188-194 (2006).
43. S. Castiglioni, E. Zuccato, E. Crisci, C. Chiabrando, R. Fanelli, and R. Bagnati. Identification and measurement of illicit drugs and their metabolites in urban wastewater by liquid chromatography-tandem mass spectrometry. Anal. Chem. 78: 8421-8429 (2006).
44. H.R. Liang, R.L. Foltz, M. Meng, and P. Bennett. Method development and validation for quantitative determination of methadone enantiomers in human plasma by liquid chromatography/tandem mass spectrometry. J. Chromatogr. B 806: 191-198 (2004).
45. W.B. Fang, D.M. Andrenyak, D.E. Moody, and E.S. Nuwayser. Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tanden mass spectrometry. J. Anal. Toxicol. 29: 169-174 (2005).
46. T.M. Annesley. Ion suppression in mass spectrometry. Clin. Chem. 49: 1041-1044 (2003).
47. U.S. FDA. Guidance for industry: bioanalytical method validation. http://www.fda/cder/guidance/4252fnl.pdf, June 2004.
48. F.T. Peters. Method validation using LC-MS. In Applications of LC-MS in Toxicology, A. Polettini, Ed. Pharmaceutical Press, London, U.K., 2006, pp 71-95.
49. J.N. Wilkins, A. Ashofteh, D. Setoda, W.S. Wheatly, H. Huigen, and W. Ling. Ultrafiltration using the Amicon MPS-1 for assessing methadone plasma protein binding. Ther. Drug Monit. 19: 83-87 (1997).
50. M.L. Stitzer, G.E. Bigelow, and I.A. Liebson. Single-day methadone dose alteration: detectability and symptoms. Clin. Pharmacol. Ther. 36: 244-250 (1984).
51. A.C. Nelson, W. Huang, and D.E. Moody. Variables in human liver microsome preparation: impact on the kinetics of l-α-acetylmethadol (LAAM) N-demethylation and dextromethorphan O-demethylation. Drug Metab. Dispos. 29: 319-325 (2001).
52. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.L. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275 (1951).
53. K.R. Allen, R. Azad, H.P. Field, and D.K. Blake. Replacement of immunoassay by LC tandem mass spectrometry for routine measurement of drugs of abuse in oral fluid. Ann. Clin. Biochem. 42: 277-284 (2005).
54. M.H. Slawson, M. Chen, D.E. Moody, S.D. Comer, E.S. Nuwayser, W.B. Fang, and R.L. Foltz. Quantitative analysis of naltrexone and 6β-naltrexol in human, rat and rabbit plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with application to the pharmacokinetics of Depotrex in rabbits. J. Anal. Toxicol. 31: 453-461 (2007).
55. S.-N. Lin, D.E. Moody, G.E. Bigelow, and R.L. Foltz. A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma. J. Anal. Toxicol. 25: 497-503 (2001).
56. D.E. Moody, M.H. Slawson, E.C. Strain, J.D. Laycock, A.C. Spanbauer, and R.L. Foltz. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a co-formulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 306: 31-39 (2002).
57. W. Huang, P.A. Bemis, M.H. Slawson, and D.E. Moody. Determination of l-α-acetylmethadol (LAAM), norLAAM, and dinor-LAAM in clinical and in vitro samples using liquid chromatography with electrospray ionization and tandem mass spectrometry. J. Pharm. Sci. 92: 10-20 (2003). 220-226